Trials / Completed
CompletedNCT01603940
Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine
Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Hospital Universitario Pedro Ernesto · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare losartan and benazepril in diabetic patients whose high blood pressure is not controlled by amlodipine and its relationship to statin current use.
Detailed description
Hypertension and diabetes mellitus are important risk factors for cardiovascular morbidity and mortality. Endothelial dysfunction and vascular rigidity are two pathophysiological mechanisms that may explain this relationship. Recent publications showed that both ACEi (angiotensin-converting enzyme inhibitor-induced) and ARB (angiotensin receptor blocker) were capable of improving vascular stiffness and endothelial function, and that these effects occurred despite blood pressure reduction. This study main objective is to assess if ARB (losartan) effects are different from ACEi (benazepril) in endothelial function in patients with diabetes mellitus type 2 and blood pressure not controlled by amlodipine and its relationship to statin current use. Secondary analysis of vascular stiffness will be measured by pulse wave velocity and augmentation index. Echocardiographic parameters, such as indexes of diastolic function, will also be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Benazepril | Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks. |
| DRUG | Losartan | Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks. |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-05-23
- Last updated
- 2016-02-01
- Results posted
- 2015-11-11
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01603940. Inclusion in this directory is not an endorsement.